Free Newsletters
Archive
My eNewsletters
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Login
Become a Member
Discussion Forums
FAQ
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Career Definitions
Labor Market Reports
Education & Training
Regions
Market Summary
News
IPOs
Company Profiles
Companies
Events
BioPharm Insight
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
 
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Feb 4, 2010 |
Taminco |
N/A |
N/A |
N/A |
$590.6M |
N/A |
N/A |
Lead Underwriter
|
Commerzbank and Rabo Securities
|
Description
|
Taminco is the world's largest producer of alkylamines and derivatives.
|
| Sep 9, 2008 |
INSYS Therapeutics |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
UBS Securities
|
Description
|
INSYS Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Sep 3, 2008 |
Codexis Pharmaceuticals |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
Credit Suisse and Goldman Sachs
|
Description
|
Codexis is a leading developer of biocatalytic chemical processes that can dramatically reduce manufacturing costs across a broad range of industries.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Aug 5, 2008 |
Zogenix, Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
N/A
|
Description
|
Zogenix is a specialty pharmaceutical company whose goal is to uniquely enhance and differentiate medicines by incorporating innovative technologies in an effort to relieve suffering in people with CNS and pain disorders.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Jun 27, 2008 |
Bayhill Therapeutics, Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
N/A
|
Description
|
Bayhill Therapeutics is a clinical-stage
biopharmaceutical company leveraging its proprietary therapeutic BHT-DNA™ platform to develop a pipeline of novel and targeted treatment candidates for autoimmune diseases.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Jun 10, 2008 |
Peplin Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
N/A
|
Description
|
Peplin is a development stage specialty pharmaceutical company, founded in 1998, focused on advancing and commercializing innovative medical dermatology products.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| May 12, 2008 |
Elixir Pharmaceuticals, Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
N/A
|
Description
|
Elixir Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Oct 8, 2007 |
ZARS Pharma
|
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
Cowen & Co and CIBC World Markets.
|
Description
|
ZARS Pharma is a specialty pharmaceutical company focused on the development and commercialization of topically administered drugs using our proprietary drug delivery technologies, primarily in the area of pain management.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Jul 27, 2007 |
Quark Pharmaceuticals
|
QURK |
$12-$14 |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
JPMorgan Chase and Bank of America.
|
Description
|
Quark is an evolving pharmaceutical company using rational drug design to develop new therapeutics for unmet medical needs.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Jun 27, 2007 |
EndoCeutics
|
ENCX |
N/A |
N/A |
$75M |
N/A |
N/A |
Lead Underwriter
|
First Albany Capital, Oppenheimer & Co. and Stifel Nicolaus will underwrite the IPO.
|
Description
|
Canada's EndoCeutics Inc., a pharmaceutical firm developing hormone therapies for breast cancer and other endocrine-related disorders.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Mar 7, 2007 |
OncoGenex Technologies Inc. |
N/A |
N/A |
N/A |
$48M |
N/A |
N/A |
Lead Underwriter
|
RBC Capital Markets will be the sole lead manager for the Offering, and the co-managers will be Needham & Company, LLC, Lazard Capital Markets LLC, Canaccord Adams Inc. and Susquehanna Financial Group, LLLP.
|
Description
|
OncoGenex is committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Dec 5, 2006 |
ImaRx Therapeutics |
N/A |
$10-$12 |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
N/A
|
Description
|
ImaRx Pharmaceutical Corp., was founded in 1991 to develop contrast agents for radiology. It is our roots in the imaging field that gave us our name: ImaRx = Imaging and pharmaceuticals (Rx).
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Oct 23, 2006 |
Asthmatx, Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
Piper Jaffray & Co. and Bear, Stearns & Co. Inc. were slated to serve as joint book-running managers for the offering, with First Albany Capital Inc. and Jefferies & Company, Inc. serving as co-managers.
|
Description
|
Asthmatx Inc. is a medical device company focused on developing and commercializing a novel therapeutic treatment for asthma.
|
| Date (Withdrawn) |
Company |
Symbol |
Price |
Shares |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Aug 4, 2006 |
Amicus Therapeutics, Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
N/A
|
Description
|
Amicus Therapeuticsis a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases.
|
| Date (Withdrawn) |
Company |
Symbol |
Price |
Shares |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Jul 27, 2006 |
Caprion Pharmaceuticals |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
N/A
|
Description
|
Caprion Pharmaceuticals Inc. is a clinical-stage biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology.
|
| Date (Withdrawn) |
Company |
Symbol |
Price |
Shares |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Jul 10, 2006 |
QUATRx Pharmaceuticals |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
N/A
|
Description
|
QuatRx is a pharmaceutical company focused on discovering, licensing, developing and commercializing compounds in the endocrine, metabolic and cardiovascular therapeutic areas.
|
| Date (Withdrawn) |
Company |
Symbol |
Price |
Shares |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Feb 17, 2006 |
Novogen Limited |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
N/A
|
Description
|
Corus Pharma is a biopharmaceutical company committed to developing and commercializing products for severe respiratory and infectious diseases that can help provide improved health and superior quality of life.
|
| Date (Withdrawn) |
Company |
Symbol |
Price |
Shares |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Jan 11, 2006 |
Glycotex, Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
N/A
|
Description
|
Glycotex, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing a novel class of drugs for human wound healing and tissue repair.
|
|
|
 |
|
|
|
|
|